A trial of cediranib and saracatanib for kidney cancer that has spread to other parts of the body (COSAK)

Overview

Cancer types:

Kidney cancer, Renal cell cancer

Status:

Results

Phase:

Phase 2

Details

This trial looked at 2 drugs called cediranib (pronounced sed-ih-ran-ib) and saracatanib (pronounced sah-rah-cat-an-ib) for a type of kidney cancer. It was for people with a type of kidney cancer called renal cell cancer that is clear cell type. To enter the trial, their cancer must have come back after having other treatment.

Recruitment start: 2 September 2010

Recruitment end: 26 January 2012

How to join

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Chief investigators

Prof Thomas Powles

Supported by

AstraZeneca

Cancer Research UK

Experimental Cancer Medicine Centre (ECMC)

ISD Cancer Clinical Trials Team

Edinburgh

National Institute for Health Research Cancer Research Network (NCRN)

Other information

This is Cancer Research UK trial number CRUKE/09/031.

Last reviewed: 11 December 2014

CRUK internal database number: 5110

Dangoor Education

About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education

Help and support

An icon of a hand shake.

Questions for your doctor

What to ask your doctor about clinical trials.

An icon of two speech bubbles, indicating a conversation.

Cancer chat forum

Meet and chat to other cancer people affected by cancer.

An icon of a landline phone.

Nurse helpline

Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.